Resonant Down 70%… Could CorMedix Inc. (CRMD) Be Next?Guest Post
Last February we warned about Resonant and since then the stock has fallen over 70%. We believe Coremedix has many of the same attributes that alarmed us about RESN. We believe CRMD is wildly overvalued, is poised for a big drop and suggest that investors avoid or consider shorting CRMD.
CorMedix has a market capitalization of $400 million, its stock is up 370% year to date, its . . .
This content is exclusively for paying members. Sign up here
If you are subscribed and having an account error please clear cache and cookies if that does not work email email@example.com or click chat